With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com The latest business developments from across Europe & Middle East
by Heather Hobbs
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
Partnership Establishes Source for Sampling and Analysis Lines
manufacturing facility supplying solutions to over 5000 laboratories in over 50 countries. With more than 300 patents, the company has been described as a perfect example of the new Chinese Industrial Revolution, moving from quantity to quality with a total focus on innovation. It has invested heavily in technology and offer complete solutions for energy from coal, biomass and recovered waste and has recently started to produce analysers for the food, and environmental Industries.
Pictured from left: Bryan Grant (Service Manager), Stella Luo (CKIC European Manager), Steve Price (General Manager), James Price (Product Manager).
Systematic Instruments Ltd has announced an exclusive distributorship for CKIC Ltd, a leading manufacturer of mechanical samplers, sample preparation equipment and analytical instruments for various applications. Already said to be the market leader in Asia, CKIC has a 100,000 m²
Systematic Instruments Ltd has many years experience in the supply and service of this type of analytical instrumentation and there is a perfect blend with CKIC product and strategic aims. Current agencies include ANKOM who make equipment for the food and agriculture sector and NCS manufacturers of elemental analysers mainly for the Metals sector. The company’s engineers are factory trained and certifi ed on all products.
44338pr@reply-direct.com
Collaboration to Develop
Gene Therapies Delivery A research collaboration is to assess the effectiveness of developing gene therapies using Avacta Group’s Affi mer technology combined with FIT Biotech Oy’s gtGTU® platform. The very small, simply structured Affi rmer proteins have ideal potential for delivering the DNA blueprint of therapeutic proteins into patient’s cells where it can be reproduced, although this natural process does needs to achieve clinically relevant levels of the protein drug to be effective.
FIT Biotech’s gtGTU, a vector for delivering genes to patients, was developed to ensure the stable and prolonged production of therapeutic proteins by the patient’s cells, in a safe manner. It removes the requirement for frequent administration of biological therapeutics which are cleared from the body after a limited time.
Dr Alastair Smith, Avacta Group Chief Executive Offi cer said: “I am delighted that we are starting this collaboration with FIT Biotech. It is a very exciting prospect and the Group is keen to see the initial data from the pilot study which we anticipate will be in the fi rst half of 2018.”
James Kuo, Chief Executive Offi cer of FIT Biotech added: “We very much look forward to working on this project together with Avacta (which) offers an exciting opportunity to take targeted therapies to a new level. This collaboration follows our strategy of bringing gtGTU to the gene therapy market through strong partnerships.”
44339pr@reply-direct.com Agreement to Progress ADC Candidates to Clinical Use
Iontas, a leader in services and platform technologies associated with the discovery and optimisation of fully human antibody drugs, is collaborating with antibody drug conjugate (ADC) development company Glythera on research to progress ADCs for diffi cult-to-treat cancers. As part of the agreement Iontas will generate human antibodies against specifi ed targets for proof-of-concept studies. Glythera will have an option for exclusive, worldwide rights to resulting antibodies for the development of ADCs alongside its proprietary conjugation platform, PermaLink® and its in-house portfolio of novel toxins, with an intention to nominate its fi rst clinical ADC candidate by 2019. Iontas will receive undisclosed development and clinical milestone payments on each of the ADCs.
Dr John McCafferty, CEO at Iontas, commented: “This Agreement refl ects the ambition of Iontas to establish
broader relationships with partners for multiple antibody deals using our proprietary technology platforms. We believe our expertise and effi ciency in antibody discovery will help Glythera with their ultimate short term goal of being in clinic by 2019.”
Dr Dave Simpson, CEO at Glythera, said: “We identifi ed Iontas as the ideal partner for antibody discovery, due to their proprietary phage display technology and libraries, providing the potential for development of multiple antibodies. The combination of Iontas’ experience and expertise, with our proven PermaLink platform, will support our mission to target diffi cult-to-treat tumours and progress towards the clinic.”
44341pr@reply-direct.com
Assay Ready Cell Lines Easier to Source in Europe
A distributor agreement signed by Gyros Protein Technologies AB will provide its customers in Europe and North America direct access to Euro Diagnostica’s iLite® assay ready cell lines, which are said to help overcome limitations of conventional cell-based assays and improve productivity.
Outsourcing Provides Optimal use of Screening Library
Pivot Park Screening Centre (PPSC, Oss, Netherlands) has outsourced management of its screening collection, containing over 300,000 compounds, to BioAscent Discovery which offers expertise in fi nding optimal use of compounds while preserving their quality.
BioAscent’s Newhouse facility offers a scalable and highly secure infrastructure for storage of compounds in solid and liquid formats and numerous tube and microplate types, from ambient to -20°C. Its reformatting capabilities have already transferred 233,000 aliquots of DMSO stock solutions from microplates into individual tubes, enabling PPSC to cherry pick ‘hit’ compounds following primary ultra-high throughput screening and to confi rm and validate their activity on the target. PPSC will also be able to undertake follow up assays faster than before.
Commenting on the agreement, Mirjam Mol-Arts MD, PPSC’s CEO said: “We want to focus on our core areas of expertise, accelerating drug discovery via ultra-high throughput screening and assay development using our leading-edge infrastructure and in-depth experience. By outsourcing the management of our collection to BioAscent we have been able to benefi t from their expertise and specialised equipment. This has helped us optimise the use of our extensive compound collection while preserving its integrity and quality, in turn enabling us to offer our customers an even more effective, fl exible and cost-effi cient service.”
44339pr@reply-direct.com
iLite technology is based upon a unique reporter gene assay format that complement those addressed by Gyros Protein Technologies’ Gyrolab™ immunoassays systems, such as pharmacokinetics studies, detection of ADA (anti-drug antibodies) and bioprocess applications. The iLite dual reporter gene format allows for normalisation of the response, eliminating unwanted matrix effects and compensating for differences in cell numbers, to achieve accurate and biologically relevant results. The cells are delivered frozen and assay ready, requiring no culture or maintenance, to enable cost reductions and time savings the company said.
44345pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the Europe and Middle East? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal International Labmate.
Email:
info@intlabmate.com
Business
Opportunities
Europe & Middle East
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
